uBiome and Arivale show the paradox of test-based health services

July 03, 2019 | Case Study

In the field of test-based health services, both uBiome and Arivale were funding front-runners, gaining $110 million and $53 million, respectively, to date. uBiome specializes in microbiome-based testing, while Arivale provided a panel of biomarker, genetic, and gut microbiome analysis. Both have made headlines recently, and not for the right reasons. In late April 2019, Arivale announced it had suspended its direct-to-consumer (D2C) business, citing the high costs of its service. Not long after, in May 2019, uBiome suspended clinical operations after potentially fraudulent business practices that prompted a raid by the U.S. FBI.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978